Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK reports positive findings from Phase III RSV vaccine trial
The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ages of 70 and 79 years.
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% effective in preventing severe illness three years after patients 60 and older first received the shot.
GSK RSV vaccine data suggest protection across 3 seasons
The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.
GSK hopes for Arexvy boost after positive Phase III data
GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of Arexvy maintains 62.9% efficacy in preventing RSV-related lower respiratory tract disease (LRTD) and 67.
GSK's RSV vaccine Arexvy shows long-term protection in Phase 3 trial
GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST 2024 Annual Meeting. In the Phase 3 trial, called AReSVi-006, a dose of Arexvy was 62.
GSK's Arexvy Shows Promising RSV Protection Over Three Seasons
GSK's Arexvy RSV vaccine demonstrated 43.3% effectiveness in preventing severe illness in its third trial season, following 94.1% effectiveness initially and 64.2% in the second year. The vaccine, one of three approved,
GSK says RSV vaccine protects against disease over three seasons
Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons
GSK Announces Positive Data From AReSVi-006 Phase III Trial For RSV Vaccine Arexvy
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating
1d
on MSN
GSK Arexvy protects from RSV over three full seasons
GSK (NYSE:GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial ...
FiercePharma
1d
GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
kffhealthnews
20h
GSK’s Widely Used RSV Shot Retains 43% Potency In Third Year, Data Show
Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...
2d
on MSN
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
GSK
RSV
GlaxoSmithKline
Pfizer
Phases of clinical research
Feedback